4.7 Review

Long non-coding RNA HOXD-AS1 in cancer

期刊

CLINICA CHIMICA ACTA
卷 487, 期 -, 页码 197-201

出版社

ELSEVIER
DOI: 10.1016/j.cca.2018.10.002

关键词

LncRNA; HOXD-AS1; Prognosis; Diagnosis; Biomarker; Therapeutic target

资金

  1. Shandong Medical and Health Science and Technology Plan Project [2015WS0193, 2014WS0067]
  2. Foundation for Outstanding Young Scientists in Shandong Province [BS2014SW019]
  3. Innovation Project of the Shandong Academy of Medical Sciences, China

向作者/读者索取更多资源

Cancer is one of the leading causes of death worldwide with a high risk of incidence and mortality. Long non coding RNAs (lncRNAs) have been shown to participate in various biological processes, including tumorigenesis and progression. The HOXD-AS1 (also known as HAGLR and Mdgt) gene is located between the HOXD1 and HOXD3 genes in the HOXD cluster and has been reported to play a critical role in the development and progression of cancers. This review summarizes the current knowledge on the biological functions and mechanisms of HOXD-AS1 in different human cancers, including bladder, cervical, colorectal, gastric, ovarian, and prostate cancers, glioma, hepatocellular carcinoma, melanoma, osteosarcoma, and non-small cell lung cancer. The aberrant expression of HOXD-AS1 in these cancers was related with clinical features of patients with cancers. HOXD-AS1 regulates the growth, invasion, and migration of tumor cells through different underlying mechanisms. In conclusion, HOXD-AS1 may be considered as a promising diagnostic/prognostic biomarker or a novel therapeutic target for cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据